Top

Published in:

01-10-2007 | Case Report

Long-standing refractory polymyositis responding to mycophenolate mofetil: a case report and review of the literature

Authors: Paola Caramaschi, Alessandro Volpe, Antonio Carletto, Lisa M. Bambara, Domenico Biasi

Published in: Clinical Rheumatology | Issue 10/2007

Abstract

The authors describe a young patient affected by long-standing polymyositis refractory to conventional treatment who showed a rapid and striking response to mycophenolate mofetil treatment.

Chan TM, Li FK, Tang CS et al (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong–Guangzhou Nephrology Study Group. N Engl J Med 343:1156–1162PubMedCrossRef

Majithia V, Harisdangkul V (2005) Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology 44:386–389PubMedCrossRef

Gelber AC, Nousari HC, Wigley FM (2000) Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 27:1542–1545PubMed

Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN (2006) Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 66:1245–1247PubMedCrossRef

Waldman MA, Callen JP (2004) Self-resolution of Epstein–Barr virus-associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate. J Am Acad Dermatol 51 (Suppl 2):S124–S130PubMedCrossRef

Edge JC, Outland JD, Dempsey JR, Callen JP (2006) Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 142:65–69PubMedCrossRef

Labioche I, Liozon E, Weschler B, Loustaud-Ratti V, Soria P, Vidal E (2004) Refractory polymyositis responding to infliximab: extended follow-up. Rheumatology 43:531–532PubMedCrossRef

Saadeh CK (2000) Etanercept is effective in the treatment of polymyositis/dermatomyositis which is refractory to conventional therapy including steroid and other disease modifying agents. Arthritis Rheum 43:S193

Hengstam GJD, Van Der Hoogen FHJ, Barbera P et al (2003) Anti-TNF blockade with infliximab (Remicade) in polymyositis and dermatomyositis. Eur Neurol 50:10–15CrossRef

10.

Uthman I, El-Sayad J (2004) Refractory polymyositis responding to infliximab. Rheumatology 43:1198–1199PubMedCrossRef

11.

Anandacoomarasamy A, Howe G, Manolios N (2005) Advanced refractory polymyositis responding to infliximab. Rheumatology 44:562–563PubMedCrossRef

12.

Marie I, Heliot P, Roussel F, Herve F, Muir JF, Levesque H (2005) Fatal mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab. Rheumatology 44:1201–1202PubMedCrossRef

13.

Roddy E, Courtney PA, Morris A (2002) Non-Hodgkin’s lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Rheumatology 41:1194–1195PubMedCrossRef

14.

Wilkes R, Sereika SM, Fertig N et al (2005) Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 52:2439–2446PubMedCrossRef

15.

Gottenberg JE, Guillevin L, Lambotte O et al (2005) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64:913–920PubMedCrossRef

16.

Lambotte O, Kotb R, Maigne G et al (2005) Efficacy of rituximab in refractory polymyositis. J Rheumatol 32:1368–1370

Title: Long-standing refractory polymyositis responding to mycophenolate mofetil: a case report and review of the literature
Authors: Paola Caramaschi
Alessandro Volpe
Antonio Carletto
Lisa M. Bambara
Domenico Biasi
Publication date: 01-10-2007
Publisher: Springer-Verlag
Published in: Clinical Rheumatology / Issue 10/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-006-0526-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2007

Latitude gradient influences the age of onset in rheumatoid arthritis patients

Rituximab for treatment-resistant extensive Wegener`s granulomatosis—additive effects of a maintenance treatment with leflunomide

Nodular pulmonary amyloidosis in a patient with rheumatoid arthritis

Unusual presentation of triple A syndrome mimicking Sjögren’s syndrome

Bone biopsy and densitometry findings in a child with Camurati–Engelmann disease

B-type natriuretic peptide (BNP) levels in female systemic lupus erythematosus patients: what is the clinical significance?

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials